<< DUSA Pharmaceuticals finds place in Deloitte's Technology Fast 500 list for second consecutive year | New health information website launched in the United Kingdom by WebMD Health >>

King Pharmaceuticals receives FDA complete response letter for CorVue NDA

Published on October 21, 2009 at 7:55 AM · No Comments

King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection. CorVue™ is a cardiac pharmacologic stress agent for use as an adjunct in SPECT (single-photon-emission computed tomographic) cardiac imaging intended for use in patients with or at risk for coronary artery disease (CAD) who are unable to perform a cardiac exercise stress test.

King is currently evaluating the FDA’s complete response letter and expects to respond to the Agency’s questions as quickly as possible.

SOURCE King Pharmaceuticals, Inc.

85a7124f-991f-44a8-b437-4b0bb74255b0|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Adenosine, Blood Vessel, Cardiovascular Disease, Coronary Artery Disease, Dyspnea, Exercise, Hospital, Neuroscience, New Drug Application, Stress

Related posts

Researchers measure ED residents' attitudes on pregnancy during residencyThe demands of a medical residency can make balancing a career and family a challenge. But the resul...
Virtual reality offers returning soldiers 'psychotherapy by computer' to treat PTSDFor those soldiers worried about the stigma associated with seeing a therapist, virtual reality appl...
New study: Talk Test is a useful indicator of VT in trained athletesThe "Talk Test" provides a simple and reliable indicator of the proper training intensity for runner...
ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meetingArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-...
MeCP2 regulatory protein determines vulnerability to cocaine addiction: ResearchA regulatory protein best known for its role in a rare genetic brain disorder also may play a critic...
Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporinIsotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc., has filed a New Dru...
Data evaluating combination therapy with REVLIMID and rituximab in patients with NHL presentedCelgene International Sàrl announced that investigational data evaluating combination therapy with R...
Common food additive lecithin may help control blood lipids and reduce disease riskScientists at Washington University School of Medicine in St. Louis have identified a substance in t...
Sex after chronic heart failureAlthough medication can help extend the lives of men with chronic heart failure, several factors ass...
Patients at high risk of stroke may need to continue Warfarin therapy after heart rhythm is controlledTreatment with warfarin, a medication that prevents blood clotting, may reduce the risk of stroke by...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.